Si Chen1, Haixia Luan1, Jianxun He1, Yan Wang1, Xiaoli Zeng1, Yongzhe Li2, Hui Yuan1. 1. Department of Clinical Laboratory Beijing Anzhen Hospital, Capital Medical University Beijing China. 2. Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College Chinese Academy of Medical Sciences Beijing China.
Abstract
BACKGROUND: C1q is a crucial component of the classical complement pathway. This study is the first to assess the association between disease activity and serum levels of C1q in Chinese Takayasu arteritis (TA) patients. METHODS: Serum C1q levels in 198 TA patients and 154 healthy controls were assessed, and the relationship between serum C1q levels and indices of TA disease activity was analyzed. Moreover, we examined the correlation between serum C1q levels and two traditional inflammatory biomarkers; erythrocyte sedimentation rate (ESR) and hypersensitive CRP (hs-CRP). RESULTS: Serum C1q levels were increased in TA patients compared with healthy controls (P = .008). TA patients with active disease had higher levels of serum C1q than patients who had inactive disease (P < .0001). In addition, treatment-naïve patients had higher serum C1q levels than those who had been treated with corticosteroids or at least one immunosuppressant (P = .001). Furthermore, a positive correlation between serum C1q levels and traditional inflammatory biomarkers in TA patients was found. The role of C1q in assessing disease activity was studied, and the area under the receiver operating characteristic curve (AUC) of C1q for predicting active disease was 0.752, and a serum cutoff value of 167.15 mg/L C1q maximized the ability of disease activity assessment, with a sensitivity/specificity of 77.80%/64.90%. When the three indicators (C1q, ESR, and hs-CRP) were combined, the AUC increased to 0.845, and the sensitivity to 84.40%. CONCLUSIONS: The serum C1q is associated with the disease activity of TA and the combination of three indicators (C1q, ESR, and hs-CRP) increases the sensitivity of disease activity assessment.
BACKGROUND: C1q is a crucial component of the classical complement pathway. This study is the first to assess the association between disease activity and serum levels of C1q in Chinese Takayasu arteritis (TA) patients. METHODS: Serum C1q levels in 198 TA patients and 154 healthy controls were assessed, and the relationship between serum C1q levels and indices of TA disease activity was analyzed. Moreover, we examined the correlation between serum C1q levels and two traditional inflammatory biomarkers; erythrocyte sedimentation rate (ESR) and hypersensitive CRP (hs-CRP). RESULTS: Serum C1q levels were increased in TA patients compared with healthy controls (P = .008). TA patients with active disease had higher levels of serum C1q than patients who had inactive disease (P < .0001). In addition, treatment-naïve patients had higher serum C1q levels than those who had been treated with corticosteroids or at least one immunosuppressant (P = .001). Furthermore, a positive correlation between serum C1q levels and traditional inflammatory biomarkers in TA patients was found. The role of C1q in assessing disease activity was studied, and the area under the receiver operating characteristic curve (AUC) of C1q for predicting active disease was 0.752, and a serum cutoff value of 167.15 mg/L C1q maximized the ability of disease activity assessment, with a sensitivity/specificity of 77.80%/64.90%. When the three indicators (C1q, ESR, and hs-CRP) were combined, the AUC increased to 0.845, and the sensitivity to 84.40%. CONCLUSIONS: The serum C1q is associated with the disease activity of TA and the combination of three indicators (C1q, ESR, and hs-CRP) increases the sensitivity of disease activity assessment.
Authors: Peter C Grayson; David Cuthbertson; Simon Carette; Gary S Hoffman; Nader A Khalidi; Curry L Koening; Carol A Langford; Kathleen Maksimowicz-McKinnon; Paul A Monach; Philip Seo; Ulrich Specks; Steven R Ytterberg; Peter A Merkel Journal: J Rheumatol Date: 2013-08-01 Impact factor: 4.666
Authors: Brooke E Gilliam; Melinda R Reed; Anil K Chauhan; Amanda B Dehlendorf; Terry L Moore Journal: Clin Exp Rheumatol Date: 2011-12-22 Impact factor: 4.473
Authors: G S Kerr; C W Hallahan; J Giordano; R Y Leavitt; A S Fauci; M Rottem; G S Hoffman Journal: Ann Intern Med Date: 1994-06-01 Impact factor: 25.391
Authors: Enrico Tombetti; Maria Chiara Di Chio; Silvia Sartorelli; Maurizio Papa; Annalaura Salerno; Barbara Bottazzi; Enrica Paola Bozzolo; Marta Greco; Patrizia Rovere-Querini; Elena Baldissera; Alessandro Del Maschio; Alberto Mantovani; Francesco De Cobelli; Maria Grazia Sabbadini; Angelo A Manfredi Journal: Arthritis Res Ther Date: 2014-11-14 Impact factor: 5.156